231 related articles for article (PubMed ID: 32730778)
21. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance.
Vredenburg MR; Ojima I; Veith J; Pera P; Kee K; Cabral F; Sharma A; Kanter P; Greco WR; Bernacki RJ
J Natl Cancer Inst; 2001 Aug; 93(16):1234-45. PubMed ID: 11504769
[TBL] [Abstract][Full Text] [Related]
22. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
Hari M; Loganzo F; Annable T; Tan X; Musto S; Morilla DB; Nettles JH; Snyder JP; Greenberger LM
Mol Cancer Ther; 2006 Feb; 5(2):270-8. PubMed ID: 16505100
[TBL] [Abstract][Full Text] [Related]
23. Dual drug-loaded nano-platform for targeted cancer therapy: toward clinical therapeutic efficacy of multifunctionality.
Ma Z; Li N; Zhang B; Hui Y; Zhang Y; Lu P; Pi J; Liu Z
J Nanobiotechnology; 2020 Sep; 18(1):123. PubMed ID: 32887626
[TBL] [Abstract][Full Text] [Related]
24. Reconstituted high density lipoprotein mediated targeted co-delivery of HZ08 and paclitaxel enhances the efficacy of paclitaxel in multidrug-resistant MCF-7 breast cancer cells.
Zhang F; Wang X; Xu X; Li M; Zhou J; Wang W
Eur J Pharm Sci; 2016 Sep; 92():11-21. PubMed ID: 27343697
[TBL] [Abstract][Full Text] [Related]
25. Comparison of cell death-inducing effect of novel taxane SB-T-1216 and paclitaxel in breast cancer cells.
Kovár J; Ehrlichová M; Smejkalová B; Zanardi I; Ojima I; Gut I
Anticancer Res; 2009 Aug; 29(8):2951-60. PubMed ID: 19661300
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in the new generation taxane anticancer agents.
Geney R; Chen J; Ojima I
Med Chem; 2005 Mar; 1(2):125-39. PubMed ID: 16787308
[TBL] [Abstract][Full Text] [Related]
27. CKT0353, a novel microtubule targeting agent, overcomes paclitaxel induced resistance in cancer cells.
Dinić J; Ríos-Luci C; Karpaviciene I; Cikotiene I; Fernandes MX; Pešić M; Padrón JM
Invest New Drugs; 2020 Jun; 38(3):584-598. PubMed ID: 31177401
[TBL] [Abstract][Full Text] [Related]
28. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.
Ferlini C; Raspaglio G; Mozzetti S; Cicchillitti L; Filippetti F; Gallo D; Fattorusso C; Campiani G; Scambia G
Cancer Res; 2005 Mar; 65(6):2397-405. PubMed ID: 15781655
[TBL] [Abstract][Full Text] [Related]
29. Multiplicity of acquired cross-resistance in paclitaxel-resistant cancer cells is associated with feedback control of TUBB3 via FOXO3a-mediated ABCB1 regulation.
Aldonza MB; Hong JY; Alinsug MV; Song J; Lee SK
Oncotarget; 2016 Jun; 7(23):34395-419. PubMed ID: 27284014
[TBL] [Abstract][Full Text] [Related]
30. Antitumour activity of novel taxanes that act at the same time as cytotoxic agents and P-glycoprotein inhibitors.
Ferlini C; Distefano M; Pignatelli F; Lin S; Riva A; Bombardelli E; Mancuso S; Ojima I; Scambia G
Br J Cancer; 2000 Dec; 83(12):1762-8. PubMed ID: 11104578
[TBL] [Abstract][Full Text] [Related]
31. Synergistic effect of paclitaxel and verapamil to overcome multi-drug resistance in breast cancer cells.
Li P; Zhong D; Gong PY
Biochem Biophys Res Commun; 2019 Aug; 516(1):183-188. PubMed ID: 31204050
[TBL] [Abstract][Full Text] [Related]
32. Long noncoding RNA CASC2 promotes paclitaxel resistance in breast cancer through regulation of miR-18a-5p/CDK19.
Zheng P; Dong L; Zhang B; Dai J; Zhang Y; Wang Y; Qin S
Histochem Cell Biol; 2019 Oct; 152(4):281-291. PubMed ID: 31352515
[TBL] [Abstract][Full Text] [Related]
33. ClC-3 promotes paclitaxel resistance via modulating tubulins polymerization in ovarian cancer cells.
Feng J; Peng Z; Gao L; Yang X; Sun Z; Hou X; Li E; Zhu L; Yang H
Biomed Pharmacother; 2021 Jun; 138():111407. PubMed ID: 33765585
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterisation of isogenic taxane resistant cell lines identify novel drivers of drug resistance.
Kenicer J; Spears M; Lyttle N; Taylor KJ; Liao L; Cunningham CA; Lambros M; MacKay A; Yao C; Reis-Filho J; Bartlett JM
BMC Cancer; 2014 Oct; 14():762. PubMed ID: 25312014
[TBL] [Abstract][Full Text] [Related]
35. D-α-tocopherol polyethylene glycol succinate-based redox-sensitive paclitaxel prodrug for overcoming multidrug resistance in cancer cells.
Bao Y; Guo Y; Zhuang X; Li D; Cheng B; Tan S; Zhang Z
Mol Pharm; 2014 Sep; 11(9):3196-209. PubMed ID: 25102234
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of resistance to cabazitaxel.
Duran GE; Wang YC; Francisco EB; Rose JC; Martinez FJ; Coller J; Brassard D; Vrignaud P; Sikic BI
Mol Cancer Ther; 2015 Jan; 14(1):193-201. PubMed ID: 25416788
[TBL] [Abstract][Full Text] [Related]
37. Tangeretin, a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function.
Feng SL; Yuan ZW; Yao XJ; Ma WZ; Liu L; Liu ZQ; Xie Y
Pharmacol Res; 2016 Aug; 110():193-204. PubMed ID: 27058921
[TBL] [Abstract][Full Text] [Related]
38. Characterization of acquired paclitaxel resistance of breast cancer cells and involvement of ABC transporters.
Němcová-Fürstová V; Kopperová D; Balušíková K; Ehrlichová M; Brynychová V; Václavíková R; Daniel P; Souček P; Kovář J
Toxicol Appl Pharmacol; 2016 Nov; 310():215-228. PubMed ID: 27664577
[TBL] [Abstract][Full Text] [Related]
39. Association of ABCB1, β tubulin I, and III with multidrug resistance of MCF7/DOC subline from breast cancer cell line MCF7.
Li W; Zhai B; Zhi H; Li Y; Jia L; Ding C; Zhang B; You W
Tumour Biol; 2014 Sep; 35(9):8883-91. PubMed ID: 24894670
[TBL] [Abstract][Full Text] [Related]
40. Apatinib Reverses Paclitaxel-resistant Lung Cancer Cells (A549) Through Blocking the Function of ABCB1 Transporter.
Zhang Q; Song Y; Cheng X; Xu Z; Matthew OA; Wang J; Sun Z; Zhang X
Anticancer Res; 2019 Oct; 39(10):5461-5471. PubMed ID: 31570440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
